Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03284164 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex
A Phase 1 study of Renal Impairment, sponsored by ContraVir Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT03284164: Completed Phase 1 study of Renal Impairment, sponsored by ContraVir Pharmaceuticals.
NCT03284164 is a Phase 1 study of Renal Impairment that has completed, run by ContraVir Pharmaceuticals. The registered enrollment target is 16 participants, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03284164, a Phase 1 study of Renal Impairment, has completed, sponsored by ContraVir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1 study to investigate the effects of Renal Impairment on the pharmacokinetics of Tenofovir exalidex
Primary Outcome
Measuring Cmax : the peak plasma concentration
Conditions Studied
Interventions
- DRUG Tenofovir Exalidex (TXL)
Study Locations (1)
Florida
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2018-02-20 |
| Phase | Phase 1 |
What the finished NCT03284164 record still lists
NCT03284164 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which Tenofovir Exalidex (TXL) is the first listed.
NCT03284164 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03284164 about?
NCT03284164 is a clinical study titled "Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex". This is a Phase 1 study to investigate the effects of Renal Impairment on the pharmacokinetics of Tenofovir exalidex
What is the current status of trial NCT03284164?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-09-28. Estimated completion is 2018-02-20.
What conditions does trial NCT03284164 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT03284164?
The interventions under investigation include: Tenofovir Exalidex (TXL) (DRUG).
Who is sponsoring clinical trial NCT03284164?
This trial is sponsored by ContraVir Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03284164 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03284164's enrollment target sits among peer trials
16 28th of 32 higher than 2 of 32 other Renal Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI